StockData
Nuvectis Pharma, Inc. logo

Nuvectis Pharma, Inc. (NVCT) stock

NVCTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 6/30
$19.20+0.09 (+0.47%)

Close on Nov 17, 2026Market cap $625.57MP/E –Yield 0.00%

Nuvectis Pharma operating income

Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.

Nuvectis Pharma's operating income for the twelve months ending Jun 30, 2026 was -$28.87M. For fiscal 2025 it was -$27.57M. The highest annual figure on record is -$12.89M in fiscal 2021.

Annual operating income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$27.57M–
FY2024Dec 31, 2024-$19.85M–
FY2023Dec 31, 2023-$22.90M–
FY2022Dec 31, 2022-$19.23M–
FY2021Dec 31, 2021-$12.89M–

Quarterly operating income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026-$7.20M–
Q1 FY2026Mar 31, 2026-$6.26M–
Q4 FY2025Dec 31, 2025-$7.62M–
Q3 FY2025Sep 30, 2025-$7.79M–
Q2 FY2025Jun 30, 2025-$6.60M–
Q1 FY2025Mar 31, 2025-$5.57M–
Q4 FY2024Dec 31, 2024-$6.45M–
Q3 FY2024Sep 30, 2024-$4.36M–
Q2 FY2024Jun 30, 2024-$4.64M–
Q1 FY2024Mar 31, 2024-$4.40M–
Q4 FY2023Dec 31, 2023-$6.87M–
Q3 FY2023Sep 30, 2023-$6.16M–
Q2 FY2023Jun 30, 2023-$5.77M–
Q1 FY2023Mar 31, 2023-$4.10M–
Q4 FY2022Dec 31, 2022-$6.78M–
Q3 FY2022Sep 30, 2022-$5.94M–
Q2 FY2022Jun 30, 2022-$3.57M–
Q1 FY2022Mar 31, 2022-$2.95M–
Q4 FY2021Dec 31, 2021-$2.27M–
Q3 FY2021Sep 30, 2021-$4.67M–
Q2 FY2021Jun 30, 2021-$5.94M–
Q1 FY2021Mar 31, 2021-$23.00K–

More Nuvectis Pharma figures

See a number that looks wrong?